We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.

International Symposium on Amyloidosis

Mayo Clinic

Poster Abstracts - DIAGNOSIS OF ATTRV

A final, consolidated overview of 16 years of data from the Transthyretin Amyloidosis Outcomes Survey PB21 (#16)

ATTR Cardiomyopathy in Early and Late onset ATTRV30M: Two Sides of the Same Coin? PB22 (#74)

Hereditary transthyretin amyloidosis with cardiomyopathy: which are the TTR variants associated with early-onset involvement? PB223 (#75)

 Motor unit remodelling as an early biomarker of disease involvement in hereditary transthyretin amyloidosis  PB24 (#127)

Serum Neurofilament light chain in hereditary transthyretin amyloidosis: Validation in real-life practice PB25 (#128)

The spectrum of neuropathy in hereditary transthyretin amyloidosis (ATTRv) in Australia PB26 (#129)

Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis - Correlation between neurofilament light chain and nerve conduction study - PB27 (#138)

Unveiling the Hidden Threat: A Case of Concurrent Mitral Regurgitation and Cardiac Amyloidosis PB28 (#221)

Ocular Involvement in Transthyretin  Amyloidosis patients - Bahia State of Brazil PB29 (#224)

Comparison of the Simoa and MSD R-PLEX assay to assess serum neurofilament light chain levels in hereditary transthyretin amyloidosis PB30 (#225)

Comparison between wild type and Val142Ile ATTR cardiomyopathy clinical presentation in the Brazilian population: Results of the Transthyretin Cardiac Amyloidosis Registry in the state of São Paulo, Brazil (REACT/SP) PB31 (#250)

Hereditary Transthyretin (ATTRv) Amyloidosis in the Middle East. The Abdali National Amyloidosis Center’s Experience PB32 (#262)

High-sensitivity cardiac troponin T to exclude cardiac involvement in TTR variant carriers and ATTRv amyloidosis patients PB33 (#272)

Navigating the Diagnostic Odyssey: Unveiling Cardiac Amyloidosis through Gastrointestinal Biopsy PB34 (#277)

CENTINNELA program: access to use of Neurofilament Light Chain for diagnosis al follow-up of patients and carriers with ATTRv PB35 (#289)

Transthyretin amyloid polyneuropathy in France: a cross-sectional study with 413 patients and real-world tafamidis meglumine use (2009-2019) PB36 (#335)

V122I Hereditary Transthyretin Amyloidosis in Brazil: an Endemic Variant PB37 (#340)

Clinical impact of Genetic Testing Screening in families with Hereditary Transthyretin Amyloidosis PB38 (#379)

ECG changes in asymptomatic ATTRv carriers developing ATTR cardiomyopathy. PB39 (#385)

Non-ATTR clinical manifestations in attr patients and carriers PB40 (#406)

ATTRv distribution in a continental multiracial country PB41 (#439)

Diagnostic yield of multigene panel analysis in patients with suspected cardiac amyloidosis PB42 (#473)

Sustained Ventricular Tachycardia as an isolated feature of transthyretin amyloidotic cardiomyopathy - Val50Met PB43 (#476)

Oxidative conversion of transthyretin in formalin-fixed clinical amyloid samples results in the formation of the His90Asp variant. PB44 (#480)

Clinical phenotype of Romanian patients with transthyretin-type hereditary amyloidosis due to Val 107 mutation PB45 (#492)

A tale of two proteins PB46 (#499)

Left Ventricular Assist Device Therapy in ATTR Cardiac Amyloid PB47 (#541)